Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC
Episode Summary
ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.